company background image
6998 logo

Genor Biopharma Holdings SEHK:6998 Stock Report

Last Price

HK$1.59

Market Cap

HK$821.3m

7D

9.7%

1Y

54.4%

Updated

11 Dec, 2024

Data

Company Financials

Genor Biopharma Holdings Limited

SEHK:6998 Stock Report

Market Cap: HK$821.3m

6998 Stock Overview

A biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. More details

6998 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Genor Biopharma Holdings Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Genor Biopharma Holdings
Historical stock prices
Current Share PriceHK$1.59
52 Week HighHK$3.25
52 Week LowHK$0.85
Beta0.62
1 Month Change-14.52%
3 Month Change-3.64%
1 Year Change54.37%
3 Year Change-78.83%
5 Year Changen/a
Change since IPO-94.31%

Recent News & Updates

Recent updates

Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment

Jun 20
Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment

Here's Why We're Watching Genor Biopharma Holdings' (HKG:6998) Cash Burn Situation

May 29
Here's Why We're Watching Genor Biopharma Holdings' (HKG:6998) Cash Burn Situation

We Think Genor Biopharma Holdings (HKG:6998) Needs To Drive Business Growth Carefully

Dec 29
We Think Genor Biopharma Holdings (HKG:6998) Needs To Drive Business Growth Carefully

We're Hopeful That Genor Biopharma Holdings (HKG:6998) Will Use Its Cash Wisely

Dec 21
We're Hopeful That Genor Biopharma Holdings (HKG:6998) Will Use Its Cash Wisely

Is Genor Biopharma Holdings (HKG:6998) In A Good Position To Deliver On Growth Plans?

Sep 05
Is Genor Biopharma Holdings (HKG:6998) In A Good Position To Deliver On Growth Plans?

We Think Genor Biopharma Holdings (HKG:6998) Can Afford To Drive Business Growth

Dec 03
We Think Genor Biopharma Holdings (HKG:6998) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About JHBP (CY) Holdings' (HKG:6998) Cash Burn Situation

Aug 28
Here's Why We're Not Too Worried About JHBP (CY) Holdings' (HKG:6998) Cash Burn Situation

Is JHBP (CY) Holdings (HKG:6998) In A Good Position To Invest In Growth?

May 10
Is JHBP (CY) Holdings (HKG:6998) In A Good Position To Invest In Growth?

Shareholder Returns

6998HK BiotechsHK Market
7D9.7%-1.8%2.5%
1Y54.4%-4.7%20.8%

Return vs Industry: 6998 exceeded the Hong Kong Biotechs industry which returned -4.7% over the past year.

Return vs Market: 6998 exceeded the Hong Kong Market which returned 20.8% over the past year.

Price Volatility

Is 6998's price volatile compared to industry and market?
6998 volatility
6998 Average Weekly Movement17.5%
Biotechs Industry Average Movement10.8%
Market Average Movement8.9%
10% most volatile stocks in HK Market18.8%
10% least volatile stocks in HK Market4.2%

Stable Share Price: 6998's share price has been volatile over the past 3 months compared to the Hong Kong market.

Volatility Over Time: 6998's weekly volatility has increased from 11% to 18% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200728Feng Guowww.genorbio.com

Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company’s principal drug candidates include GB242, an infliximab (Remicade) biosimilar for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric crohn’s disease, and fistulizing crohn’s disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for treating breast cancer; and GB492, a stimulator of interferon genes in combination with GB226, which is under Phase 1/2 clinical trial to treat solid tumors. It also develops GB226, which is in Phase III clinical trial to treat 2L+ cervical cancer; in phase II trial to treat ASPS and r/r PMBCL; and in Phase I trial to treat 2L/3L+ EGFR+ NSCLC and 2L+ mCRC.

Genor Biopharma Holdings Limited Fundamentals Summary

How do Genor Biopharma Holdings's earnings and revenue compare to its market cap?
6998 fundamental statistics
Market capHK$821.25m
Earnings (TTM)-HK$562.04m
Revenue (TTM)HK$15.48m

53.1x

P/S Ratio

-1.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6998 income statement (TTM)
RevenueCN¥14.47m
Cost of RevenueCN¥349.00k
Gross ProfitCN¥14.12m
Other ExpensesCN¥539.63m
Earnings-CN¥525.50m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.02
Gross Margin97.59%
Net Profit Margin-3,631.69%
Debt/Equity Ratio0%

How did 6998 perform over the long term?

See historical performance and comparison